Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy

doi:10.3748/wjg.v20.i34.12355

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 34

This Article

(257)

(274)

(0)

(5181)

(11)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Report

World J Gastroenterol. Sep 14, 2014; 20(34): 12355-12358
Published online Sep 14, 2014. doi: 10.3748/wjg.v20.i34.12355

Full Size Figure Download Figure

Figure 1 Fluorescence in situ hybridization analysis showing positive human epidermal growth factor receptor 2 expression with cluster amplification (ratio > 2. 2).

Citation: Dong CX, Fu JF, Ye XY, Li XF, Zhong X, Yuan Y. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. World J Gastroenterol 2014; 20(34): 12355-12358
URL: https://www.wjgnet.com/1007-9327/full/v20/i34/12355.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i34.12355

Dong CX, Fu JF, Ye XY, Li XF, Zhong X, Yuan Y. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. World J Gastroenterol 2014; 20(34): 12355-12358 [PMID: 25232273 DOI: 10.3748/wjg.v20.i34.12355]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.